Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Pregnant women are particularly vulnerable to malaria infections. Multidrug resistance in Plasmodium falciparum seriously compromises treatment in some endemic areas. Between April 1999 and October 2001, we treated and prospectively followed 27 Karen pregnant women with multiple recrudescent P. falciparum infections who were resistant to all other antimalarials with a triple combination of artesunate-atovaquone-proguanil. The treatment was well tolerated and we found no evidence of toxicity for the mothers and the fetus. All but 1 woman were cured (cure rate 96%, 95% CI 89-100). The triple combination of artesunate (4 mg/kg/d), atovaquone (20 mg/kg/d), and proguanil (8 mg/kg/d) may provide a much needed, albeit expensive, 3-d rescue treatment for pregnant women exposed to multidrug- resistant P. falciparum malaria.

Original publication

DOI

10.1016/s0035-9203(03)80040-8

Type

Journal article

Journal

Trans R Soc Trop Med Hyg

Publication Date

09/2003

Volume

97

Pages

592 - 594

Keywords

Adolescent, Adult, Antimalarials, Artemisinins, Artesunate, Atovaquone, Drug Resistance, Multiple, Drug Therapy, Combination, Female, Humans, Malaria, Falciparum, Naphthoquinones, Pregnancy, Pregnancy Complications, Parasitic, Pregnancy Outcome, Proguanil, Sesquiterpenes